Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

World map of global burden of bacterial antimicrobial resistance, colour-coded by country, showing the percentage of Klebsiella pneumoniae isolates with resistance to cephalosporin
Fluoroquinolone-resistant Escherichia coli (2019) (Source: Lancet)

20th January 2022 – Based on estimates across 204 countries and territories, the Global burden of bacterial antimicrobial resistance in 204 countries and territories in 2019 paper provides the most comprehensive estimates of the global impact of antibiotic resistance to date and reveals that AMR has now become a leading cause of death globally. Published in The Lancet following rigorous external peer review by independent experts, the paper highlights specific areas of concern and equips governments and health communities with the information they need to act quickly and develop a proportionate response.

Estimates included in the paper show that AMR is a leading cause of death globally, higher than HIV/AIDs or Malaria.

Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death.

Common infections such as lower respiratory tract infections, bloodstream infections, and intra-abdominal infections are now killing hundreds of thousands of people every year because bacteria have become resistant to treatment. This includes historically treatable illnesses, such as pneumonia, hospital-acquired infections, and foodborne ailments. An estimated 4.95 million people who died in 2019 suffered from at least one drug-resistant infection and AMR directly caused 1.27 million of those deaths.

Everyone is at risk from AMR, but the data shows that young children are particularly affected. In 2019, one in five deaths attributable to AMR occurred in children under the age of five – often from previously treatable infections.

Sub-Saharan Africa faces the highest burden, with 255,000 deaths due to AMR in just one year and a particularly high number from vaccine preventable pneumococcal bacterial disease. However, high income countries also face alarmingly high levels, most notably for Escherichia coli, which commonly causes kidney infections, and Staphylococcus aureus, which is often acquired in hospitals and can cause bloodstream infections.

Current action plans on AMR are not ambitious or fast enough to control the threat.

Past projections estimated that as many as 10 million annual deaths from AMR could occur by 2050. In 2022, as we now have access to these robust estimates, we know that we are already far closer to this figure than expected. AMR is already threatening the ability of hospitals to keep patients safe from infections and undermining the ability of doctors to carry out essential medical practice safely, including surgery, childbirth and cancer treatment since infection is a risk following these procedures.

We are not innovating fast enough to develop effective vaccines, medicines and treatments:

  • Between 1980 and 2000, 63 new antibiotics were approved for clinical use. Between 2000 and 2018, just 15 additional antibiotics were approved.
  • Out of the seven deadliest drug-resistant bacteria, vaccines are only available for two (Streptococcus pneumoniae and Mycobacterium tuberculosis).
  • Whilst all seven of the leading bacteria have been identified as ‘priority pathogens’ by the World Health Organization (WHO) only two have been a focus of major global health intervention programmes – S. pneumoniae (primarily through pneumococcal vaccination) and M. tuberculosis.

And with high levels of hospitalisations from COVID-19, there is a risk that the burden of AMR has already accelerated due to increased use of antibiotics. However, more evidence is needed to ascertain the true impact.

Discussing the importance of the new estimates to direct urgent action, Director of the Institute for Health Metrics and Evaluation, Professor Chris Murray said:

“This paper is a critical step that allows us to see the full scale of the challenge. We now need to leverage these estimates to course-correct action and drive innovation if we want to stay ahead in the race against AMR.”

The GRAM leadership team at the University of Oxford, Prof Christiane Dolecek, Dr Catrin Moore, and Prof Benn Sartorius, also commented:

“Being able to measure AMR, and compare it with other major health threats, is essential to addressing its serious consequences. This work incorporates the best available data and provides reliable evidence describing the substantial mortality and morbidity caused by AMR globally. We anticipate that policymakers will use these results as we intended them, to drive action.”

New estimates from the paper were pre-released to Health Ministers at the G7 in June 2021, who agreed that AMR must be prioritised as part of plans to strengthen global health systems.

Talking about the need for political action on AMR, UK Special Envoy on Antimicrobial Resistance, Dame Sally Davies said:

“AMR is already one of the greatest challenges facing humanity. Behind these new numbers are families and communities who are tragically bearing the brunt of the silent AMR pandemic. We must use this data as a warning signal to spur on action at every level.”

There are immediate actions that can help countries around the world protect their health systems against the threat of AMR:

  • We need to take greater action to monitor and control infections, globally, nationally and within individual hospitals.
  • We must accelerate our support for infection prevention and control, as well as expand access to vaccines and clean water and sanitation.
  • We must optimise our use of antibiotics unrelated to treating human disease, such as in food and animal production, taking a One Health approach and recognising the interconnection between human and animal health.
  • It’s time to be more thoughtful about our use of antimicrobial treatments – expanding access to lifesaving antibiotics where needed, minimising use where they are not necessary to improve human health, and acting according to WHO Global Action Plan and AWaRE guidelines .
  • We must increase funding at every stage of the development pipeline for new antimicrobials targeting priority pathogens - from research for high priority bacteria, such as K. pneumoniae and E. coli, to securing access through innovative market solutions.

Authors of the paper are hopeful that, with this new data, the world is better equipped than ever to correct the trajectory. COVID-19 has demonstrated the importance of global commitments to infection and control measures, such as hand washing and surveillance, and rapid investments in treatments.

Talking about the lessons learnt from COVID-19, Head of Intervention, Infectious Disease at Wellcome Trust, Tim Jinks said:

“The COVID-19 pandemic has highlighted the importance of global collaboration: political leaders, the healthcare community, the private sector and the public working together to tackle a global health threat. Like COVID-19, we know what needs to be done to address AMR, but we must now come together with a sense of urgency and global solidarity if we are to be successful.”

Similar stories

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Registration is open for The Global Health Network Conference 2022

To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.

Gail Carson chair of GOARN

Dr Gail Carson from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is nominated chair of WHO Global Outbreak Alert & Response Network (GOARN)

Enhanced vaccination against Japanese encephalitis virus could reduce encephalitis prevalence by one third in SE Asia

Encephalitis is a worldwide public health issue, with a substantially high burden among children in Southeast Asia. A large study of the causes of childhood encephalitis in SE Asia suggests that enhanced and effective vaccination against the Japanese encephalitis virus alone could reduce encephalitis prevalence by one third.

RECOVERY trial celebrates two-year anniversary of life-saving dexamethasone result

Two years ago, the RECOVERY trial gave the world its first breakthrough against coronavirus: the discovery that an inexpensive steroid pill, dexamethasone, reduced deaths by up to a third from COVID-1. Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.